Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy
Source: Understanding and Implementing the AASLD’s HBV Practice Guidelines and Other Recent Guidelines and Recommendations on the Diagnosis, Management, and Treatment of Hepatitis B

Slideset

Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy

In this downloadable slideset, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on HBV screening, diagnosis, and treatment candidacy.
Format: Microsoft PowerPoint (.ppt)
File size: 5.78 MB
Date posted: 11/11/2010
  • Treating HBV Patients With Cirrhosis: The Need for Vigilant HCC Screening

    Maria Buti MD - 5/14/2014    6 comments / Last Comment: 10/3/2014
    Antiviral therapy can dramatically improve liver histology, even in cirrhotic patients, but it remains critical to screen patients with suppressed viral load for hepatocellular carcinoma.
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis

    Nezam H. Afdhal MD, FRCPI - 11/4/2014    6 comments / Last Comment: 12/9/2014
    New regimens are becoming available for genotype 1 HCV infection that offer more data and apparently better efficacy than previously recommended regimens in patients with cirrhosis who have experienced previous treatment failure.
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014    8 comments / Last Comment: 8/13/2014
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • All-Oral Therapy for HCV: Rewriting the Course of the Disease

    Nancy Reau MD - 11/3/2014    5 comments / Last Comment: 12/9/2014
    All-oral HCV therapies are erasing the importance of traditional obstacles to cure
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014    3 comments / Last Comment: 10/24/2014
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.